Showing results (1471-1480 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|March 17, 2015
Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk PopulationsRoland Diel, Niklas Lampenius, Albert NienhausPharmacoeconomics|April 5, 2021
Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer SurvivorsJackie Yim, Joanne Shaw, Rosalie Viney, et al.Pharmacoeconomics|September 12, 2012
A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New ZealandRajan Ragupathy, Katri Aaltonen, June Tordoff, et al.Pharmacoeconomics|September 6, 2012
Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costsDaniel T Grima, Lisa M Bernard, Elizabeth S Dunn, et al.Pharmacoeconomics|August 20, 2020
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020)Michael Urbich, Gary Globe, Krystallia Pantiri, et al.Pharmacoeconomics|March 22, 2015
Simulation and matching-based approaches for indirect comparison of treatmentsK Jack Ishak, Irina Proskorovsky, Agnes BenedictPharmacoeconomics|May 24, 2014
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UKAlex Diamantopoulos, A Finckh, T Huizinga, et al.Pharmacoeconomics|May 2, 2023
Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life DimensionsJames Love-Koh, Paul Schneider, Simon McNamara, et al.Pharmacoeconomics|July 3, 2014
Cost-Effectiveness Analysis of Qsymia for Weight LossEric A Finkelstein, Eliza Kruger, Sunil KarnawatPharmacoeconomics|February 4, 2015
A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registryHedwig M Blommestein, Margreet G Franken, Carin A Uyl-de GrootPageof 336